http://www.mdrnainc.com () —
Marina Biotech, Inc. (NASDAQ: MRNAD), formerly known as MDRNA, Inc., a
leading RNAi-based drug discovery and development company, today
announced that J. Michael French, Marina's President and Chief
Executive Officer, will provide an overview of the Company and its
progress in key programs at the following upcoming conferences:
A live audio webcast of each presentation will be available on the
Event Calendar pages of the Investors section of the Company's website
at http://www.marinabio.com (http://www.marinabio.com) . Please allow
time prior to the presentation to register and download any necessary
software. A replay of the presentation will be available on the
Investors section of the Marina Biotech website under Event Calendar
approximately one hour after the live presentation and will be
archived for three months.
About Marina Biotech, Inc.
Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology
company, focused on the development and commercialization of
therapeutic products based on RNA interference (RNAi). Marina's
pipeline currently includes a clinical program in Familial Adenomatous
Polyposis (a precancerous syndrome) and two preclinical programs -- in
hepatocellular carcinoma and bladder cancer. Marina's goal is to
improve human health through the development of RNAi-based compounds
and drug delivery technologies that together provide superior
therapeutic options for patients. Additional information about Marina
Biotech is available at http://www.marinabio.com
(http://www.marinabio.com) .